DE69109557D1 - Überzogene feste Arzneiform mit Verabreichungsmöglichkeit im Dickdarm. - Google Patents

Überzogene feste Arzneiform mit Verabreichungsmöglichkeit im Dickdarm.

Info

Publication number
DE69109557D1
DE69109557D1 DE69109557T DE69109557T DE69109557D1 DE 69109557 D1 DE69109557 D1 DE 69109557D1 DE 69109557 T DE69109557 T DE 69109557T DE 69109557 T DE69109557 T DE 69109557T DE 69109557 D1 DE69109557 D1 DE 69109557D1
Authority
DE
Germany
Prior art keywords
administration
possibility
large intestine
solid drug
drug form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69109557T
Other languages
English (en)
Other versions
DE69109557T2 (de
Inventor
Fujio Sekigawa
Yoshiro Onda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shin Etsu Chemical Co Ltd
Original Assignee
Shin Etsu Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Etsu Chemical Co Ltd filed Critical Shin Etsu Chemical Co Ltd
Publication of DE69109557D1 publication Critical patent/DE69109557D1/de
Application granted granted Critical
Publication of DE69109557T2 publication Critical patent/DE69109557T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
DE69109557T 1990-07-10 1991-07-05 Überzogene feste Arzneiform mit Verabreichungsmöglichkeit im Dickdarm. Expired - Fee Related DE69109557T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2182157A JP2773959B2 (ja) 1990-07-10 1990-07-10 大腸内放出性固形製剤

Publications (2)

Publication Number Publication Date
DE69109557D1 true DE69109557D1 (de) 1995-06-14
DE69109557T2 DE69109557T2 (de) 1995-09-28

Family

ID=16113355

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69109557T Expired - Fee Related DE69109557T2 (de) 1990-07-10 1991-07-05 Überzogene feste Arzneiform mit Verabreichungsmöglichkeit im Dickdarm.

Country Status (8)

Country Link
US (1) US5217720A (de)
EP (1) EP0466566B1 (de)
JP (1) JP2773959B2 (de)
KR (1) KR960006063B1 (de)
CN (1) CN1037933C (de)
AU (1) AU633220B2 (de)
CA (1) CA2046739C (de)
DE (1) DE69109557T2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
WO1994004135A1 (en) * 1992-08-13 1994-03-03 Teikoku Seiyaku Kabushiki Kaisha Oral preparation for release in lower digestive tracts
US5356634A (en) * 1992-11-13 1994-10-18 Eastman Chemical Company Controlled-release delivery system
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
JP2917799B2 (ja) * 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
AU1751997A (en) * 1996-01-30 1997-08-22 Advanced Polymer Systems Inc. Targeted delivery of drugs to the lower gastrointestinal tract
JPH10513202A (ja) * 1996-06-11 1998-12-15 ゾナジェン，インコーポレイテッド キトサン薬物送達システム
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6248362B1 (en) * 1997-03-26 2001-06-19 Meiji Seika Kaisha, Ltd. Large intestinal delivery composite
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
WO2000074720A1 (fr) * 1999-06-09 2000-12-14 Mochida Pharmaceutical Co., Ltd. Systeme de liberation dans les voies digestives inferieures
JP4524009B2 (ja) * 1999-08-09 2010-08-11 大日本住友製薬株式会社 大腸内放出性カプセル製剤
EP1203590B1 (de) * 1999-08-09 2007-07-04 Dainippon Sumitomo Pharma Co., Ltd. Chitosanpulver enthaltende feste zubereitungen und verfahren zu deren herstellung
US6475493B1 (en) 1999-09-02 2002-11-05 Norstrum Pharmaceuticals, Inc. Controlled release pellet formulation
AUPQ672800A0 (en) * 2000-04-06 2000-05-04 Natraherbal Pty Ltd Garlic supplement for deodoriser
TWI241195B (en) * 2000-04-10 2005-10-11 Shionogi & Co Preventive agent for bile acidic diarrhea
JP4875277B2 (ja) * 2000-06-16 2012-02-15 田辺三菱製薬株式会社 放出ｐＨ域及び／又は速度制御組成物
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
KR100404769B1 (ko) * 2001-01-31 2003-11-10 주식회사 비에스텍 팬에 부착된 향 송풍장치
AU2002244295B2 (en) * 2001-03-13 2006-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid
KR100413114B1 (ko) * 2001-03-30 2003-12-31 재단법인서울대학교산학협력재단 키토산으로 표면 코팅된 조직 재생용 생분해성 고분자제제 및 그 제조방법
US6590059B2 (en) 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
DE102004040243A1 (de) * 2003-08-22 2005-03-17 Heppe, Katja, Dipl.-Biotechnol. Transportsystem auf Chitosanbasis
KR100782918B1 (ko) * 2003-09-19 2007-12-07 펜웨스트 파머슈티칼즈 컴파니 지연 방출성 제형
EP1663156A2 (de) * 2003-09-19 2006-06-07 Penwest Pharmaceuticals Company Chronotherapeutische dosierformen
CA2554771A1 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
WO2005102292A1 (en) * 2004-03-23 2005-11-03 Lytone Enterprise, Inc. Chitosan embedded or encapsulated capsule
CN1956707B (zh) * 2004-03-26 2010-12-29 力奇制药公司 包含n-(2-(2-苯二酰亚氨基乙氧基)-乙酰基)-l-丙氨酰基-d-谷氨酸(lk-423)的耐胃酸的药物剂型
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
EP2324886A1 (de) 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Neue deuterierte Analoga des Tadalafils
WO2007016338A2 (en) * 2005-07-29 2007-02-08 Goverment Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Use of chk2 kinase inhibitors for cancer treatment
WO2007109175A1 (en) 2006-03-17 2007-09-27 Johns Hopkins University School Of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
WO2008075448A1 (ja) * 2006-12-21 2008-06-26 Aicello Chemical Co., Ltd. キトサン溶液及び該溶液から形成されたキトサンコーティング製剤
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
AU2008304200B2 (en) * 2007-09-26 2013-12-19 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
KR101115501B1 (ko) * 2007-11-30 2012-02-27 주식회사 키토라이프 시플로플록사신이 담지된 저분자량 수용성 키토산 미립자에고분자가 코팅된 다중입자 및 이의 제조방법
PL2278975T3 (pl) 2008-05-07 2017-02-28 Cardioxyl Pharmaceuticals Inc. Nowe związki nitrozowe jako donory nitroksylu i metody ich zastosowania
JP5670325B2 (ja) 2008-06-19 2015-02-18 エックスカバリー ホールディング カンパニー エルエルシー キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
EP2350012B1 (de) 2008-10-06 2017-06-28 The Johns Hopkins University Chinolinverbindungen als angiogenese-, humane methioninaminopeptidase- und sirt1-hemmer sowie verfahren zur behandlung von erkrankungen
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CN102753519B (zh) 2009-12-07 2015-08-05 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物
ES2719101T3 (es) * 2009-12-07 2019-07-08 Univ Johns Hopkins Derivados de hidroxilamina N-acilados y derivados de hidroxilamina o-acilados
ES2610226T3 (es) 2010-10-08 2017-04-26 Xcovery Holding Company Llc Compuestos de 6-amino-piridazin-3-il-carboxamida sustituidos como moduladores de proteínas cinasas
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
AU2012305915B2 (en) 2011-09-07 2017-09-07 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal
MX363306B (es) 2011-10-17 2019-03-20 Univ Johns Hopkins Derivados del acido de meldrum, acido barbiturico y pirazolona sustituidos con hidroxilamina como donadores de nitroxilo (hno).
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
JP5836980B2 (ja) * 2013-01-11 2015-12-24 信越化学工業株式会社 薬物含有粒子、固形製剤及び薬物含有粒子の製造方法
TR201802211T4 (tr) 2013-01-18 2018-03-21 Cardioxyl Pharmaceuticals Inc Geliştirilmiş terapötik indekse sahip nitroksil vericiler.
KR102341899B1 (ko) 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
JP6435179B2 (ja) * 2014-12-08 2018-12-05 フロイント産業株式会社 大腸ドラッグデリバリーシステム錠剤
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
MX2017008373A (es) 2014-12-23 2017-10-19 Cerecor Inc Compuestos, composiciones y metodos.
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
KR20180038440A (ko) 2015-06-09 2018-04-16 렉산 파마슈티컬스, 인코포레이티드 플루오로사이클로펜테닐시토신 용도 및 제조 방법
JP2018526392A (ja) 2015-09-04 2018-09-13 レクサン ファーマシューティカルズ インコーポレイテッド キノキサリニル−ピペラジンアミドの使用方法
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
JP7089141B2 (ja) 2016-10-03 2022-06-22 ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド 新規なｊａｋ１選択的阻害剤およびその使用
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
CN112352052A (zh) 2018-05-04 2021-02-09 托利斯有限公司 激活上皮细胞和髓样细胞的tlr3配体
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020215037A1 (en) 2019-04-18 2020-10-22 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
US20220193033A1 (en) * 2019-04-30 2022-06-23 Dsm Ip Assets B.V. New delivery system for specific water-soluble vitamins
US20220226254A1 (en) * 2019-04-30 2022-07-21 Dsm Ip Assets B.V. New delivery system for fat soluble vitamins
JP2023528805A (ja) 2020-05-26 2023-07-06 ディオニス セラピューティクス インコーポレイテッド 核酸人工ミニプロテオームライブラリー
EP4161508A1 (de) 2020-06-05 2023-04-12 Henry Ford Health System Dakalasvir zur verwendung bei der behandlung von lungen- und prostatakrebs
EP4267554A1 (de) 2020-12-22 2023-11-01 Mekanistic Therapeutics LLC Substituierte aminobenzylheteroarylverbindungen als egfr- und/oder pi3k-hemmer
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
EP4385510A1 (de) 2021-08-10 2024-06-19 Betta Pharmaceuticals Co., Ltd Verwendung von ensartinib oder einem salz davon bei der behandlung von krankheiten mit exon-skipping-mutation von met 14
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
CN115192537B (zh) * 2022-07-27 2024-03-26 康普药业股份有限公司 一种甲磺酸萘莫司他组合物及其制备方法
CN117426267A (zh) * 2023-12-21 2024-01-23 山东科赛基农生物工程有限公司 水稻生产全程健康管理方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
BR8506634A (pt) * 1984-12-20 1986-09-09 Rhone Poulenc Sante Composicoes para o revestimento de aditivos alimentares destinados aos ruminantes e granulados sob forma de microcapsulas assim revestidos
FR2582909B1 (fr) * 1985-06-07 1991-05-10 Aec Chim Organ Biolog Produit pour l'alimentation des ruminants et sa preparation.
JPH02107060A (ja) * 1988-10-17 1990-04-19 Matsushita Electric Ind Co Ltd 画信号処理方法
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
JPH0813748B2 (ja) * 1990-04-23 1996-02-14 帝國製薬株式会社 大腸崩壊性ポリペプチド系経口製剤

Also Published As

Publication number Publication date
KR920002135A (ko) 1992-02-28
EP0466566A3 (en) 1992-12-09
EP0466566A2 (de) 1992-01-15
CN1037933C (zh) 1998-04-08
AU8027291A (en) 1992-01-16
CN1058904A (zh) 1992-02-26
EP0466566B1 (de) 1995-05-10
CA2046739C (en) 2000-02-29
JPH0469333A (ja) 1992-03-04
CA2046739A1 (en) 1992-01-11
US5217720A (en) 1993-06-08
AU633220B2 (en) 1993-01-21
DE69109557T2 (de) 1995-09-28
KR960006063B1 (ko) 1996-05-08
JP2773959B2 (ja) 1998-07-09

Similar Documents

Publication Publication Date Title
DE69109557D1 (de) Überzogene feste Arzneiform mit Verabreichungsmöglichkeit im Dickdarm.
DE3688532D1 (de) Pharmazeutische darreichungsform mit verzoegerter abgabe.
DE3882848D1 (de) Kosmetikbasiszubereitung mit arzneimitteleigenschaften.
NL194578B (nl) Farmaceutisch preparaat met cyclosporine.
DE69115229D1 (de) Arzneimittel.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
MX9203602A (es) Administracion iontoforetica mejorada de farmacos.
ATE98480T1 (de) Arzneimittelformulierungen.
DE69224941D1 (de) Arzneimittelabgabekatheter
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
DE3681348D1 (de) Oral-arzneizubereitung mit retardwirkung.
DE69427472D1 (de) Arzneimittel mit kontrollierter Wirkstoffabgabe
DE3884237D1 (de) Beschichtete Kunststoffolie und daraus hergestelltes Kunststofflaminat.
NO883591D0 (no) Dermal administreringsform.
DE3782840D1 (de) Arzneimittel mit verzoegerter freigabe.
DE68920797D1 (de) Herzmittel.
FI911652A0 (fi) Farmaceutisk beredning av nitroglycering foer perkutan administration.
DE3879111D1 (de) Pharmazeutische kautablette mit geschmaksmaskierung.
NO911429L (no) Stoffbehandling.
FR2675802B1 (fr) Antiserotonines, leur preparation et les medicaments les contenant.
DE69214310D1 (de) Pranoprofen enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe
NO892764L (no) Medikamentell administreringsform for droevtyggere.
FI905236A0 (fi) Deoxiribonukleosider innehaollande farmaceutiska konsistenser foer laekning av saor.
MX9200532A (es) Agente farmaceuticos.
NO911430L (no) Stoffbehandlingsmetode.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee